TORONTO, May 18 /CNW/ - Patheon Inc. (TSX: PTI), a leading provider of
contract development and manufacturing services to the global
pharmaceutical industry, announced today that it will report its second
quarter fiscal 2011 financial results on Friday, June 10, 2011.
In conjunction with its financial results announcement, Patheon will
host a conference call with financial analysts on Friday, June 10, 2011
at 10:00 a.m. (EDT). The financial results news release will be issued
at approximately 7:00 a.m. (EDT) on Friday, June 10, 2011.
Interested parties are invited to access the live meeting and conference
call, via telephone, in listen-only mode, toll free at 1-888-231-8191
(U.S., including Puerto Rico) and 1-647-427-7450 (Canada and
International). Listeners are encouraged to dial in five to fifteen
minutes in advance to avoid delays. A live audio will also be available
via the web at http://www.patheon.com. (Please note that Windows Media Player or RealPlayer is required).
A telephone replay of the conference call will be available between
Friday, June 10, 2011 and Friday, June 17, 2011 by dialling
1-800-642-1687 (toll free) or 1-403-451-9481, and by entering identification number
68566376, followed by the number key. The conference call will also be
archived at http://www.patheon.com.
Patheon Inc. (TSX: PTI) is a leading global provider of contract
development and manufacturing services to the global pharmaceutical
industry. The company provides the highest quality products and
services to approximately 300 of the world's leading pharmaceutical and
biotechnology companies. Its services range from preclinical
development through commercial manufacturing of a full array of dosage
forms including parenteral, solid, semi-solid and liquid forms.
Patheon uses many innovative technologies including single-use
disposables, liquid-filled hard capsules and a variety of modified
The company's comprehensive range of fully integrated Pharmaceutical
Development Services includes pre-formulation, formulation, analytical
development, clinical manufacturing, scale-up and commercialization.
Patheon can take customers direct to clinic with global clinical
packaging and distribution services and Patheon's Quick to Clinic™
programs can accelerate early phase development projects to clinical
trials while minimizing the consumption of valuable API. The company's
integrated development and manufacturing network of 10 manufacturing
facilities, and eight development centers and one clinical trial
material packaging facility across North America and Europe, enables
customer products to be launched with confidence anywhere in the world.
SOURCE Patheon Inc.
For further information:
Investor Relations and Corporate Communications